NCT01651351View on ClinicalTrials.gov

GLASSIA Infusion Rate Study

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 16, 2013

Study Completion Date

January 16, 2013

Conditions
Alpha1-antitrypsin DeficiencyHealthy Volunteers
Interventions
BIOLOGICAL

Alpha1-proteinase inhibitor

GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.

BIOLOGICAL

Placebo: Human albumin 2.5%

Intravenous administration

Trial Locations (1)

66211

Overland Park

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT01651351 - GLASSIA Infusion Rate Study | Biotech Hunter | Biotech Hunter